Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Urologic Neoplasms 1Thyroid Neoplasms 1Soft Tissue Neoplasms 1Sarcoma 1Recurrence 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Lymphangioleiomyomatosis 1Erdheim-Chester Disease 1Endocrine Gland Neoplasms 1Castleman Disease 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 9Specimen Handling 8Cisplatin 5Cetuximab 5Platinum 41,2-diaminocyclohexaneplatinum II citrate 4cemiplimab 3Radiotherapy 3Immunoglobulin G 3Disulfides 3Biopsy 3(225)Ac-DOTA-c(RGDyK) 3pembrolizumab 2Radiotherapy, Intensity-Modulated 2Radiation 2Nivolumab 2Carboplatin 2Bevacizumab 2trastuzumab deruxtecan 1temsirolimus 1niraparib 1ipatasertib 1durvalumab 1dostarlimab 1cabozantinib 1atezolizumab 1Valproic Acid 1Ultrasonography 1Transurethral Resection of Bladder 1Tramadol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mouth Neoplasms × Valproic Acid × 30 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡